Read Trending Stories
- » Consumer Biz Recap: Talbots Shares CRASH HARD, Time Warner Eyes Sports Website
- » Global Investors Opt for Safety as Spain Remains Scary
- » Do Spain's Red Flags Scream Caution?
- » Consumer Biz Recap: Toyota Needs New Markets, Wal-Mart's Express Update
- » Yahoo: You'll Forget Chrome and Safari When You See This
Today's Trending Stocks
Click a Company to Research Now:
- Bank of America (BAC)
- Apple . (AAPL)
- Facebook (FB)
- AT&T (T)
- Nokia (NOK)
- Delcath Systems (DCTH)
- Mentor Graphics Corp (MENT)
- Complete Genomics (GNOM)
Delcath Systems (NASDAQ:DCTH) is trading higher today following a weekend announcement that data form a Phase 3 trial of its chemosaturation system showed extended survival rates for patients with melanoma metastases in the liver.
Cleveland BioLabs (NASDAQ:CBLI) has announced that Russian investment firm Rusnano will spend up to $26 million over the next four years to help fund a new unit that will develop preclinical drug candidates.
Johnson & Johnson (NYSE:JNJ) has received FDA approval for using Remicade on pediatric patients with ulcerative colitis.
ImmunoGen (NASDAQ:IMGN) is trading higher on positive results for a clinical trial of Roche’s (PINK:RHHBY) T-DM1 breast cancer drug, for which ImmunoGen will collect royalties.
Ariad Pharmaceuticals (NASDAQ:ARIA) has announced positive long-term results for a Phase 1 trial of its leukemia treatment.
Mela Sciences (NASDAQ:MELA) shares have skyrocketed over 80% today on news that the FDA had issued an “approvable letter” for its medical devices that aims to help doctors more accurately diagnose melanoma.
Don’t Miss: Walgreen Company Fourth Quarter Earnings Sneak Peek
Teva Pharmaceuticals (NASDAQ:TEVA) has announced the buyout of a partner’s interest in a joint venture in Japan for $150 million. The company expects that coming under full ownership of its Japanese operations will drive pharmaceutical sales higher.
Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!
Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.
Click here now for your FREE trial to our acclaimed flagship newsletter:
